Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Teresa Troiani et al.|The Lancet Oncology|2016Cited by 1k
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trialAndrea Sartore‐Bianchi, Alberto Bardelli, Filippo Pietrantonio et al.|Nature Medicine|2022Cited by 259
Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate CancerF. Porpiglia, Stefano De Luca, Matteo Manfredi et al.|European Urology|2016Cited by 201
The Roles of Multiparametric Magnetic Resonance Imaging, PCA3 and Prostate Health Index—Which is the Best Predictor of Prostate Cancer after a Negative Biopsy?F. Porpiglia, Daniele Regge, Filippo Russo et al.|The Journal of Urology|2014Cited by 71
Contents of this issueJane Adam, Yasuyuki Yamashita, M. Tann et al.|Clinical Radiology|2008Cited by 0